Dysautonomia and hyponatraemia as harbingers of Guillain-Barre syndrome

Shah, Preet Mukesh; Dhakre, Vijay Waman; Veerasuri, Ramya; Bhabhor, Anand

doi:10.1136/bcr-2018-226925

Cited by 4 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hypertension occurs in 60%-70% of patients with AIDP and marked fluctuations in the blood pressure is an indicator of poor prognosis. (17).…”

Section: Discussionmentioning

confidence: 99%

Aidp Before and After Covid-19 in Algeria: Short Cohort Study

T. Ait Mouheb,

L. Ait Mokhtar,

Z. Amine

2023

EPRA

View full text Add to dashboard Cite

Acute inflammatory demyelinating polyradiculoneuropathy is an immune-mediated polyneuropathy (AIDP) that manifests in the form of an acute, ascending, areflexic, progressive and symmetrical paralysis. The primary infection usually from the respiratory or gastrointestinal tract and can be bacterial or viral, and during the pandemic SARS -COV2 and COVID-19 vaccine may also lead to it Life-threatening complications can occur as a result of Acute inflammatory demyelinating polyradiculoneuropathy Syndrome, such as: Severe Autonomic Cardiovascular Dysfunction and respiratory distress. We will report cases who were admitted to the ICU at Lamine Debaghine hospital between 2018 and 2023 presenting major complications and their evolution under ICU ward assistance. CATEGORY: Resuscitation and Anesthesia, Emergency Medicine KEYWORDS: Acute inflammatory demyelinating polyradiculoneuropathy syndrome, dysautonomia, ICU, AIDP, Guillain-Barre.

show abstract

“…Hypertension occurs in 60%-70% of patients with AIDP and marked fluctuations in the blood pressure is an indicator of poor prognosis. (17).…”

Section: Discussionmentioning

confidence: 99%

Aidp Before and After Covid-19 in Algeria: Short Cohort Study

T. Ait Mouheb,

L. Ait Mokhtar,

Z. Amine

2023

EPRA

View full text Add to dashboard Cite

show abstract

“…Micro-organisms more rarely triggering GBS include scrub typhus (Tsutsugamishi fever) [ 46 ], Chikungunya [ 47 ], rubella virus [ 45 ], VZV, Toscana virus, hepatitis-C, hepatitis-A, hepatitis-B, West Nile, COVID-19, SARS-CoV-2, or Zika [ 48 ]. Rare, non-infectious triggers of GBS include hyponatriemia [ 49 ], bariatric surgery [ 50 ], lupus, pregnancy [ 42 ], or bacterial meningitis [ 51 ]. Antibodies associated with GBS include GM1/GD1a (AIDP), GM1/GT1a/GD1a (AMAN), or GD1a/GQ1b (AMSAN) [ 42 ].…”

Section: Acquired Neuropathiesmentioning

confidence: 99%

Orphan Peripheral Neuropathies

Finsterer

Löscher

Wanschitz

et al. 2021

JND

View full text Add to dashboard Cite

Objectives: Generally, neuropathies of peripheral nerves are a frequent condition (prevalence 2–3%) and most frequently due to alcoholism, diabetes, renal insufficiency, malignancy, toxins, or drugs. However, the vast majority of neuropathies has orphan status. This review focuses on the etiology, frequency, diagnosis, and treatment of orphan neuropathies. Methods: Literature review Results: Rareness of diseases is not uniformly defined but in the US an orphan disease is diagnosed if the prevalence is <1:200000, in Europe if <5:10000. Most acquired and hereditary neuropathies are orphan diseases. Often the causative variant has been reported only in a single patient or family, particularly the ones that are newly detected (e.g. SEPT9, SORD). Among the complex neuropathies (hereditary multisystem disorders with concomitant neuropathies) orphan forms have been reported among mitochondrial disorders (e.g. NARP, MNGIE, SANDO), spinocerebellar ataxias (e,g, TMEM240), hereditary spastic paraplegias (e.g UBAP1), lysosomal storage disease (e.g. Schindler disease), peroxisomal disorders, porphyrias, and other types (e.g. giant axonal neuropathy, Tangier disease). Orphan acquired neuropathies include the metabolic neuropathies (e.g. vitamin-B1, folic acid), toxic neuropathies (e.g. copper, lithium, lead, arsenic, thallium, mercury), infectious neuropathies, immune-mediated (e.g. Bruns-Garland syndrome), and neoplastic/paraneoplastic neuropathies. Conclusions: Though orphan neuropathies are rare per definition they constitute the majority of neuropathies and should be considered as some of them are easy to identify and potentially treatable, as clarification of the underlying cause may contribute to the knowledge about etiology and pathophysiology of these conditions, and as the true prevalence may become obvious only if all ever diagnosed cases are reported.

show abstract

“…Guillain-Barré syndrome is a severe illness due to the abrupt and unexpected development of weakness and, in most cases, complete paralysis. Fortunately, 70% of patients having GBS typically recover completely [1]. Individual with respiratory failure generally survives with diligent intensive care and effective treatment of infection, autonomic dysfunction, and other medical problems [1].…”

Section: Introductionmentioning

confidence: 99%

“…Fortunately, 70% of patients having GBS typically recover completely [1]. Individual with respiratory failure generally survives with diligent intensive care and effective treatment of infection, autonomic dysfunction, and other medical problems [1].…”

Section: Introductionmentioning

confidence: 99%

Guillain-Barré Syndrome: A Rare Case Report

Dhanvijay

Ankar

2021

JPRI

View full text Add to dashboard Cite

Introduction: Guillain-Barré syndrome (GBS) is a rare neurodegenerative condition in which the immune system of the body mistakenly damages a portion of the peripheral nerve system. The initial signs are general weakness and numbness in the limbs. Initial symptoms occur within a few days or weeks of infection. These symptoms can spread fast, ultimately paralyzing the entire body. The peripheral system consists of the brain and spinal cord. The nerve network is found outside of the brain and spinal cord. GBS can range from a minor case with short weakness to a completely fatal paralysis that renders the individual unable to breathe on their own. Fortunately, even the most severe instances of GBS may be recovered from. Some people will remain feeble even after they have recovered. The majority of patients reach the peak of their weakness within the first two weeks of symptoms appearing; by the third week, 90 percent of those affected are at their weakest. Symptoms of muscle weakness include difficulty with muscles of the eyes and vision, swallowing difficulties, difficulty in speaking, or chewing, pricking or pins and needles sensations in the hands and feet, pain that can be severe, especially at night, coordination problems, and unsteadiness, abnormal heartbeat/rate or blood pressure, problems with digestion and/or bladder control, and problems with digestion and/or bladder control. Background: Guillain-Barré syndrome can affect anyone. It can attack at any age (though it is more common in adults and the elderly), and both sexes are equally susceptible to the condition. GBS is predicted to afflict one in every 100,000 people each year. GBS affects between 3,000 and 6,000 persons in the United States each year. Case Presentation: A 53 years old male patient came to the hospital with the chief complaint of weakness in all four limbs for 6 days. A patient was apparently alright 6 days back later he was experience weakness in the left side of the body following covid vaccination on 4th June, weakness was gradually progressive in nature and progress to the right side of the body after 2 days. Later on, 8th of June patient got admitted to GMC yavatmal where the routine investigation was done including a CT scan brain which normal and doctors ask for an MRI brain for which the patient and his relative had taken a DAMA discharge and brought the patient to AVBR Hospital. All investigation has been done after that the physician diagnosed the patient having Guillain barre syndrome. The patient weakness has been worse and the treatment start according to the disease condition. Medical treatment including physical therapy also been started to reducing physical weakness and the patient condition is improved day by day. Intervention: The intervention was given to the patient such as injection ceftriaxone 1 gm BD, Inj pan 40 mg OD, Inj Emset 4 mg TDS, Inj optinurone 1 Amp in 100 ml normal saline.

show abstract

Dysautonomia and hyponatraemia as harbingers of Guillain-Barre syndrome

Cited by 4 publications

References 22 publications

Aidp Before and After Covid-19 in Algeria: Short Cohort Study

Aidp Before and After Covid-19 in Algeria: Short Cohort Study

Orphan Peripheral Neuropathies

Guillain-Barré Syndrome: A Rare Case Report

Contact Info

Product

Resources

About